Although Johnson & Johnson is powerful and is also an industry leader, it has taken a very different path from Pfizer.
What is Johnson & Johnson’s philosophy?
Decentralization = creativity = productivity!
The Johnson & Johnson Group made its fortune by making sterile dressings, but the truly world-renowned product is not a sterile dressing. It might just be a "Band-Aid" created by one of its employees who cut his finger while cooking, or it might be Johnson & Johnson diapers, etc...
Johnson & Johnson has always believed that small and fully authorized units can create new products and develop new markets. Therefore, it has tried to maintain a small and independent company and is responsible for its own production, marketing, distribution and research and development. It also maintains its independence after acquiring new companies and continues to
Split into independent companies within the existing organization.
Today, Johnson & Johnson has 150 companies, of which more than 20 are major companies, and the rest are newly acquired companies or spin-offs from these 20 companies.
Each company is independent and 100% owned by Johnson & Johnson. Under the philosophy of decentralization and innovation, Johnson & Johnson grew fourfold in the 10 years from 1972 to 1982. Sales in 1982 reached US$3.3 billion, and the number of employees worldwide
With a total of 79,000 employees, the annual return on shareholders' equity is nearly 20%. In recent years, with the advantages of marketization and the mobilization of the World Trade Organization, the advantages of this model have been fully explored, and it has gone further and further.
However, Johnson & Johnson has already cooperated with China. In 1985, Johnson & Johnson established its first joint venture in China, Xi'an Janssen Pharmaceutical Co., Ltd. Subsequently, it established Shanghai Johnson & Johnson Co., Ltd., Johnson & Johnson (China) Co., Ltd.,
Johnson & Johnson (China) Medical Devices Co., Ltd. and Shanghai Johnson & Johnson Pharmaceutical Co., Ltd.
With the continuous development of its business, Johnson & Johnson today has more than 6,000 employees in China and produces a wide range of products, including consumer goods and personal care products, pharmaceutical products, medical equipment and diagnostic products.
However, the core competitiveness of Johnson & Johnson is not within these branches. These companies are just a commodity economy similar to an enterprise.
Johnson & Johnson has begun to change in recent years and began to emphasize the core, because the expansion of external products is only value-added business, not core competitiveness.
Just like the development of Xiaomi Group, within a period of time, it can rely on product diversification to continuously expand the market. However, if it lacks a core competitiveness, Xiaomi's future will be limited.
At this point, Bai Ye had already had further communication with Mr. Lei, and the other party had already begun preparations.
As a large international enterprise, how could Johnson & Johnson fail to understand this?
Therefore, Bai Ye approached the Johnson & Johnson Group this time, hoping to have core exchanges with Johnson & Johnson and strengthen each other.
In fact, compared to Pfizer, Bai Ye values some aspects of Johnson & Johnson more, that is, the cooperation area with the Johnson & Johnson Group. This guy is too big, just like a behemoth, and its subsidiaries are basically involved in health-related peripheral industries.
.
Therefore, cooperation with Johnson & Johnson can not only drive the development of medicine, but even the development of the entire economy.
China's manufacturing industry is still well-known in the world. For example, the ten-year-old lawsuit between Johnson & Johnson and China's Guilin Zhonghui Company over blood sugar test strips shows that the people of the Chinese nation have never lacked creativity and productivity.
Moreover, Bai Ye's current development model of the Check and Balance Group is very similar to the current Johnson & Johnson Group!
However, the marketing model is different.
The product coverage of Check and Balance Group is very high, and it has basically contracted Bai Ye's lottery in recent years. However, Check and Balance Group is not as well-known as Johnson & Johnson, which limits its market.
Bai Ye feels that the Check and Balance Group needs to be listed on the market, and they can definitely take advantage of the turmoil surrounding the launch of the Puxicon drug to allow the Check and Balance Group to go public smoothly.
His cooperation with Johnson & Johnson is in the field of medical equipment.
Bai Ye still has a precious opportunity to designate upgraded items. He can take advantage of this opportunity and enter the medical testing market with the help of the Johnson & Johnson Group's platform.
This market is weak in China!
Bai Ye has not wanted to enter quickly because medical treatment, such as physiological and biochemical tests, complex large-scale CT machines, nuclear magnetic resonance, etc., definitely requires more than just the medical field, but involves physics, chemistry and many other fields.
cooperation in the field.
So, it's definitely not as simple as you think.
What Bai Ye wants to take advantage of now is that strengthening opportunity. He hopes to cooperate with the Johnson & Johnson Group and go further in developing medical testing equipment.
In fact, Spom Company is the most suitable group in this field, but the only thing that is not cooperative is that after several interactions between Spom Company and Bai Ye, it was found that this company's attitude towards the country made Bai Ye uncomfortable.
So, Bai Ye found Johnson & Johnson.
If Johnson & Johnson's core technology can be kept in China and benefit China, the contribution will be great.
The person who made the appointment with Johnson & Johnson this time was not the Chinese company Johnson & Johnson, but Mr. Heath, the chief engineer of the Johnson & Johnson headquarters in the United States.
After seeing Bai Ye, Heath smiled: "Professor Bai Ye, you are young and promising."
Bai Ye smiled, shook his head and said, "Compared with Mr. Heath, there is still a gap. I want to meet you today to talk to you about our cooperation."
Heath's eyes lit up: "Are you willing to hand over Proxicon to us? Professor Bai Ye, if this is the case, you will not regret what you did today. I believe that our Johnson & Johnson Group can definitely afford it.
Satisfactory numbers!”
Bai Ye shook his head: "No, no, no, it's not Puxicon. It's another item."
Heath heard this and smiled: "Oh? Haha, is it about your research team's research progress on tumor cells in this study? Maybe this news surprises me even more!"
Bai Ye continued to shake his head: "No, my cooperation with Johnson & Johnson is not on tumor research, nor on the development of new drugs, because what your company is good at is not the development of new drugs. To be honest, I don't think we can do joint research with your company.
Oncology is a good choice, and Pfizer has gone further than your company in oncology research and development."
"Also, to be honest with Mr. Heath, I have had some communication with Pfizer's management. I hope to conduct in-depth research and cooperation with Pfizer Group. We are willing to work together in tumor research and development."
When Heath heard this, his expression suddenly changed!
This is not good news!
Pfizer and Johnson & Johnson have always been competitors. Although there is no precise competition between certain products, there have always been small frictions.
Even in order to prevent the other party from becoming the industry leader, there are many obstacles for the other party.
if……
Heath no longer dared to think about it. When he thought about this possibility, he felt a little...scared?